Volitionrx (VNRX) Cash & Equivalents (2011 - 2025)

Volitionrx's Cash & Equivalents history runs 11 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Cash & Equivalents fell 65.78% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 65.78% YoY) and the FY2025 annual result came in at $1.1 million, down 65.78% from the prior year.
• Cash & Equivalents was $1.1 million for Q4 2025 at Volitionrx, up from $199407.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $33.1 million in Q1 2021 and bottomed at $199407.0 in Q3 2025.
• A 5-year average of $12.6 million and a median of $10.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 559.07% — and 2025, when it plunged 96.32%.
• Volitionrx's Cash & Equivalents stood at $20.6 million in 2021, then tumbled by 47.2% to $10.9 million in 2022, then jumped by 90.76% to $20.7 million in 2023, then plunged by 84.25% to $3.3 million in 2024, then plunged by 65.78% to $1.1 million in 2025.
• Business Quant data shows VNRX's Cash & Equivalents at $1.1 million in Q4 2025, $199407.0 in Q3 2025, and $2.3 million in Q2 2025.